Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SZSE:002399.SZ

11.65 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 5,421.6697,159.4116,365.1775,332.0754,624.6544,814.9652,670.2062,260.9322,292.31,958.8611,513.1691,761.822,494.5813,853.4482,224.124435.221299.382277.795
Cost of Revenue 3,746.2594,825.014,332.1383,244.2692,899.1762,884.7182,030.1971,537.5961,443.5721,393.4871,136.9651,094.4421,774.5382,231.6711,150.47190.822195.26192.048
Gross Profit 1,675.412,334.4012,033.0392,087.8061,725.4781,930.247640.009723.336848.728565.374376.204667.378720.0431,621.7771,073.654244.399104.12285.747
Gross Profit Ratio 0.3090.3260.3190.3920.3730.4010.240.320.370.2890.2490.3790.2890.4210.4830.5620.3480.309
Reseach & Development Expenses 173.145252.142221.099160.008148.714186.85379.6362.04597.17359.45839.97230.08825.525158.5560000
General & Administrative Expenses 458.572146.494142.341150.766128.329125.992119.148136.739112.779127.2956.31133.58140.88135.60394.16936.16617.28322.898
Selling & Marketing Expenses 517.416518.502430.493408.901411.32290.27363.58242.17223.06713.0345.8814.4744.9553.7073.6962.3272.0212.009
SG&A 906.833664.996572.835559.667539.649416.265182.73178.911135.846140.32562.19238.05445.83739.3197.86638.49219.30424.907
Other Expenses -855.38294.714274.94241.301208.1369.711.90640.00547.2217.0014.5751.7131.270.3372.020.370.36-0.01
Operating Expenses 1,935.3581,211.8521,068.874960.975896.499845.393450.609457.109398.715324.28224.77175.991148.713229.9298.88938.79419.69125.112
Operating Income -259.9481,135.136773.2031,329.9561,314.734721.148-7.402435.611643.896390.182375.258727.006719.5721,416.626959.766197.89573.1951.94
Operating Income Ratio -0.0480.1590.1210.2490.2840.15-0.0030.1930.2810.1990.2480.4130.2880.3680.4320.4550.2440.187
Total Other Income Expenses Net -220.435-305.285-550.94-2.1190.202-354.006-184.894208.712240.529155.515227.548237.095148.68825.056-12.979-8.192-10.882-8.705
Income Before Tax -480.383829.851222.2631,327.8361,314.936730.8484.505474.939690.542396.61378.983728.483720.0191,416.913961.786197.41273.5551.93
Income Before Tax Ratio -0.0890.1160.0350.2490.2840.1520.0020.210.3010.2020.250.4130.2890.3680.4320.4540.2460.187
Income Tax Expense -126.175115.164-11.12306.204271.382138.664-113.68488.821122.46461.27865.563111.932101.081208.118152.72936.0195.3894.046
Net Income -783.258727.426240.7881,024.211,059.356616.194131.33396.892579.777338.278317.335624.393622.0831,209.503809.057161.39368.16147.884
Net Income Ratio -0.1440.1020.0380.1920.2290.1280.0490.1760.2530.1730.210.3540.2490.3140.3640.3710.2280.172
EPS -0.530.50.160.760.850.490.160.320.460.260.250.490.491.960.70.560.240.17
EPS Diluted -0.530.50.160.760.850.490.160.320.460.260.250.490.491.960.70.560.240.17
EBITDA 124.721,442.7951,075.9471,962.7291,952.9591,185.667348.641743.173880.746483.542407.649511.146732.1661,434.895981.464212.33891.19658.732
EBITDA Ratio 0.0230.2020.1690.3680.4220.2460.1310.3290.3840.2470.2690.290.2940.3720.4410.4880.3050.211